BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 30792754)

  • 1. Perspectives on immunotherapy via oncolytic viruses.
    Reale A; Vitiello A; Conciatori V; Parolin C; Calistri A; Palù G
    Infect Agent Cancer; 2019; 14():5. PubMed ID: 30792754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Oncolytic Viruses in the Treatment of Melanoma.
    Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
    Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
    Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
    Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy.
    Reale A; Calistri A; Altomonte J
    Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy.
    Ban W; Guan J; Huang H; He Z; Sun M; Liu F; Sun J
    Nano Res; 2022; 15(5):4137-4153. PubMed ID: 35194488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral Immunotherapy-Update 2019.
    Hamid O; Ismail R; Puzanov I
    Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review: Oncolytic virotherapy, updates and future directions.
    Fountzilas C; Patel S; Mahalingam D
    Oncotarget; 2017 Nov; 8(60):102617-102639. PubMed ID: 29254276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy.
    Zhang T; Jou TH; Hsin J; Wang Z; Huang K; Ye J; Yin H; Xing Y
    J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.
    Wang X; Shen Y; Wan X; Hu X; Cai WQ; Wu Z; Xin Q; Liu X; Gui J; Xin HY; Xin HW
    J Transl Med; 2023 Jul; 21(1):500. PubMed ID: 37491263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
    Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
    Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy with oncolytic viruses: progress and challenges.
    Shalhout SZ; Miller DM; Emerick KS; Kaufman HL
    Nat Rev Clin Oncol; 2023 Mar; 20(3):160-177. PubMed ID: 36631681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
    Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
    Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?
    Zhang S; Rabkin SD
    Expert Opin Drug Discov; 2021 Apr; 16(4):391-410. PubMed ID: 33232188
    [No Abstract]   [Full Text] [Related]  

  • 14. Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers.
    Ziogas DC; Martinos A; Petsiou DP; Anastasopoulou A; Gogas H
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune System, Friend or Foe of Oncolytic Virotherapy?
    Filley AC; Dey M
    Front Oncol; 2017; 7():106. PubMed ID: 28589085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances.
    Zheng M; Huang J; Tong A; Yang H
    Mol Ther Oncolytics; 2019 Dec; 15():234-247. PubMed ID: 31872046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
    Russell L; Peng KW; Russell SJ; Diaz RM
    BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic Viruses in Cancer Treatment: A Review.
    Lawler SE; Speranza MC; Cho CF; Chiocca EA
    JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements.
    Jin KT; Du WL; Liu YY; Lan HR; Si JX; Mou XZ
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33546172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic virotherapy in cancer treatment: challenges and optimization prospects.
    Chen L; Zuo M; Zhou Q; Wang Y
    Front Immunol; 2023; 14():1308890. PubMed ID: 38169820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.